High Levels of PARP, FANCD2 and P53 on Risk of 3-Year Recurrence.

<p>*Adjusted for age, cancer status (grade, histology type and stage) at diagnosis and the presence of residual tumor at surgery.</p

Patients' Baseline Characteristics.

<p>Patients' Baseline Characteristics.</p

The Associations of P53, BRCAness Profile and Residual Tumor with 3-year Recurrence-Free Survival.

<p>*Negative is defined as no or weak staining; positive is defined as moderate or strong staining.</p

Immunocytochemistry.

<p>Immunocytochemistry.</p

Associations of PARP and/or FANCD2 with P53.

<p>Association between PARP, FANCD2, and P53. Patients with positive PARP or positive FANCD2 were more likely to have positive P53. Patients positive for both PARP and FANCD2 were statistically more likely to stain positive for P53.</p

Kaplan-Meier Estimated 3-Year Recurrence-Free Survival Curves.

<p>Kaplan-Meier estimated 3-year recurrence-free survival curves. <b>A:</b> No difference in recurrence-free survival when each of the 5 mutually exclusive groups by expression of PARP, FANCD2, and P53 were examined independently. <b>B:</b> Patients positive for all three PARP, FANCD2, and P53 had lower recurrence-free survival compared to patients not positive for all three.</p

Association of rs2256787 in the <i>ARHGEF10L</i> gene with invasive endometrioid EOC risk by study site and combined.

<p>Squares represent the estimated per-allele odds ratio (OR) and are proportional to sample size for each study; lines indicate its 95% confidence interval (CI); source indicates contributing study;[<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0197561#pone.0197561.ref011" target="_blank">11</a>] MAF, control minor allele frequency; PVal, per-allele p-value adjusted for age, site, and principal components to account for residual differences in European ancestry.</p

Association of variants in small GTPase genes with epithelial ovarian cancer risk (p-value<10⁻⁴) and functional annotation.

<p>Association of variants in small GTPase genes with epithelial ovarian cancer risk (p-value<10⁻⁴) and functional annotation.</p

The most significant SNPs in the transport pathway genes and risk of EOC by histology, invasiveness, and race/ethnicity¹.

<p>¹ INV: all invasive EOC combined; LMP: low malignant potential / borderline tumors; SER: serous; CC: clear cell; End: endometrioid; Muc: mucinous. Statistically significant associations are indicated in bold (P<0.05). Data format is the following: OR (95% CI); p-value; FDR q-value (white-European women). Only significant FDRs (q<0.2) are shown (<i>HEPH</i>: INV and SER<i>; UGT1A</i>: End).</p><p>The most significant SNPs in the transport pathway genes and risk of EOC by histology, invasiveness, and race/ethnicity<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0128106#t001fn001" target="_blank">¹</a>.</p

Top SNPs associated with SER EOC across racial groups.

<p>¹ MAF, minor allele and its frequency</p><p>² p-value <0.05 are in bold</p><p>³ Odds ratio, 95% confidence interval</p><p>Top SNPs associated with SER EOC across racial groups.</p